Unlocking the Uveoscleral Pathway: Adam Szaronos on Bio-Interventional Innovation in Glaucoma

In this edition of The Rob & Jai Show , the OIS Podcast welcomes Adam Szaronos, CEO of IanTrek, for a wide-ranging conversation on innovation, leadership, and unlocking new pathways in glaucoma care. Adam walks us through his career journey from Alcon to TearLab to leading IanTrek, where he’s now championing a new class of glaucoma procedures with AloeFlow™—a minimally invasive, tissue-based implant that activates the uveoscleral pathway. Together with hosts Dr. Rob Rothman and Dr. Jai Parekh, Adam discusses: The evolution of his career from medical device sales to surgical commercialization and C-suite leadership. Why the uveoscleral pathway, long leveraged in pharmacology, has remained unaddressed in surgical glaucoma—and how IanTrek is changing that. The material science breakthrough that differentiates AloeFlow™ from past uveoscleral attempts like CyPass. The market opportunity for post-MiGs patients and how IanTrek’s platform opens new treatment options without burning surgical real estate. Insights into IanTrek’s growing bio-interventional pipeline and what’s ahead in 2025 and beyond. Whether you’re a glaucoma surgeon, an investor, or a medtech strategist, this episode is a must-listen on where glaucoma innovation is headed.

You can listen to Unlocking the Uveoscleral Pathway: Adam Szaronos on Bio-Interventional Innovation in Glaucoma online on Radio and Podcast. Open the player on this page to stream the available audio.

Unlocking the Uveoscleral Pathway: Adam Szaronos on Bio-Interventional Innovation in Glaucoma is an episode from OIS Podcast by OIS Podcast.

This episode is 38:05 long.

This episode was published on Apr 25, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from OIS Podcast when more episodes are available from the podcast feed.